首页> 外文期刊>International journal of urology: official journal of the Japanese Urological Association >Alteration of apoptotic regulatory molecules expression during carcinogenesis and tumor progression of renal cell carcinoma.
【24h】

Alteration of apoptotic regulatory molecules expression during carcinogenesis and tumor progression of renal cell carcinoma.

机译:肾细胞癌的癌变和肿瘤进展过程中凋亡调控分子表达的变化。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: In order to characterize the alteration of apoptotic regulatory molecule expressions during carcinogenesis and tumor progression of renal cell carcinoma (RCC), we compared the expressions between tumor and normal tissues, and evaluated the relationships between expressions in tumors with pathological and clinical characteristics. METHODS: Reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC) allowed the determination of Fas, Fas ligand (FasL), and bcl-2 mRNA expressions in surgically resected tissues of 40 cases of RCC. RESULTS: In comparing the mRNA expression incidence between tumor and normal tissues, RT-PCR analysis demonstrated that the Fas and bcl-2 incidence in tumors was significantly lower than that in normal tissues. An IHC analysis was supportive of the RT-PCR results that higher immunoreactivity was recognized in mRNA positive cases than in negative cases. With regard to relationships with pathological and clinical characteristics, FasL mRNA expression was recognized significantly more frequently in pT3a tumors than in pT1 tumors, and also more frequently in G2 tumors than in G1 tumors. A similar result was obtained by IHC analysis. Five patients died of cancer. Four of these patients had tumors which showed positive mRNA expression and a strong immunoreactivity of FasL. CONCLUSION: It is suggested that the alteration of the down-regulated expression of Fas and bcl-2 might contribute to the carcinogenesis of RCC. It is also suggested that the alteration of up-regulated expression of FasL in tumors, which establishes the immune evasion mechanism in some malignancies, might be characterized during the tumor progression of RCC.
机译:背景:为了表征肾细胞癌(RCC)癌变和肿瘤进展过程中凋亡调控分子表达的变化,我们比较了肿瘤与正常组织之间的表达,并评估了肿瘤表达与病理和临床特征之间的关系。方法:通过逆转录聚合酶链反应(RT-PCR)和免疫组化(IHC)技术可以测定40例RCC手术切除组织中的Fas,Fas配体(FasL)和bcl-2 mRNA的表达。结果:在比较肿瘤与正常组织的mRNA表达发生率时,RT-PCR分析显示,肿瘤中Fas和bcl-2的发生率明显低于正常组织。 IHC分析支持RT-PCR结果:与阴性病例相比,mRNA阳性病例的免疫反应性更高。关于与病理和临床特征的关系,在pT3a肿瘤中比在pT1肿瘤中更频繁地识别FasL mRNA表达,并且在G2肿瘤中也比在G1肿瘤中更频繁地识别FasL mRNA表达。通过IHC分析获得了相似的结果。五名患者死于癌症。这些患者中有四个患有肿瘤,这些肿瘤显示出阳性的mRNA表达和FasL的强免疫反应性。结论:Fas和bcl-2表达下调可能与RCC的癌变有关。还提示在RCC的肿瘤发展过程中,可能会表征FasL在肿瘤中表达上调的改变,从而在某些恶性肿瘤中建立了逃避免疫的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号